Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.

Qian, Xiaoyan; Chen, Haizhu; Tao, Yunxia

Qian, Xiaoyan; Chen, Haizhu; Tao, Yunxia.

Affiliation

Qian X; Department of Oncology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China.
Chen H; Breast Tumor Centre, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Tao Y; Phase I Clinical Trial Centre, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Front Immunol ; 14: 1146898, 2023.

Article in En | MEDLINE | ID: mdl-37063822

Subject(s)

Epstein-Barr Virus Infections; Nasopharyngeal Neoplasms; Humans; Immune Checkpoint Inhibitors/therapeutic use; Nasopharyngeal Neoplasms/drug therapy; Nasopharyngeal Neoplasms/complications; Epstein-Barr Virus Infections/complications; B7-H1 Antigen/metabolism; Biomarkers, Tumor/metabolism; Herpesvirus 4, Human/metabolism; Nasopharyngeal Carcinoma/drug therapy; Nasopharyngeal Carcinoma/complications

Key words

Epstein-Barr virus; PD-L1 expression; biomarker; immune checkpoint inhibitors; immunotherapy; meta-analysis; nasopharyngeal cancer; tumor mutation burden

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nasopharyngeal Neoplasms / Epstein-Barr Virus Infections Type of study: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: China Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google